Wesley Jessen, a CIBA Vision Company, Files Patent Infringement Lawsuit Against CooperVision, Inc.

Apr 23, 2001, 01:00 ET from CIBA Vision Corporation

    ATLANTA, April 23 /PRNewswire Interactive News Release/ -- CIBA Vision
 Corporation, announced today that Wesley Jessen Corporation, a CIBA Vision
 Company, has filed a lawsuit against CooperVision, Inc. in the California
 Federal District Court for infringement of patent rights protecting its unique
 colored contact lens technology.
     The lawsuit claims that CooperVision's Frequency(R) Colors contact lenses
 infringe on the patents that protect Wesley Jessen's FreshLook(R) brand of
 contact lenses.
     CIBA Vision is seeking to have the Court prohibit CooperVision from
 selling its infringing product.
     "This patent protects the innovative color technology of the FreshLook
 brand of contact lenses," said Scott Meece, vice president and general counsel
 for CIBA Vision.  "We are confident that we will prevail and we are eager to
 bring this case to trial.  We will take all steps necessary to prevent others
 from infringing on our intellectual property rights."
     CooperVision recently began selling its Frequency Colors in Florida and
 Puerto Rico.  CIBA Vision also has patent infringement litigation involving
 Frequency Colors pending in Germany, France and the U.K.
     CIBA Vision acquired Wesley Jessen on October 2, 2000, in an all cash
 transaction valued at $785 million.
     With worldwide headquarters in Atlanta, CIBA Vision is a global leader in
 research, development and manufacturing of optical and ophthalmic products and
 services, including contact lenses, lens care products and ophthalmic surgical
 products.  CIBA Vision products are available in more than 70 countries.  For
 more information, visit the CIBA Vision website at www.cibavision.com .
     CIBA Vision is the eye care unit of Novartis AG (NYSE:   NVS), a world
 leader in healthcare with core businesses in pharmaceuticals, consumer health,
 generics, eye care and animal health.  In 2000, the Group's ongoing businesses
 achieved sales of CHF 29.1 billion (USD 17.2 billion) and invested
 approximately CHF 4.0 billion (USD 2.4 billion) in R&D.  Headquartered in
 Basel, Switzerland, Novartis employs about 66,000 people and operates in more
 than 140 countries around the world.  For further information, please consult
 www.novartis.com .
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X18926423
 
 

SOURCE CIBA Vision Corporation
    ATLANTA, April 23 /PRNewswire Interactive News Release/ -- CIBA Vision
 Corporation, announced today that Wesley Jessen Corporation, a CIBA Vision
 Company, has filed a lawsuit against CooperVision, Inc. in the California
 Federal District Court for infringement of patent rights protecting its unique
 colored contact lens technology.
     The lawsuit claims that CooperVision's Frequency(R) Colors contact lenses
 infringe on the patents that protect Wesley Jessen's FreshLook(R) brand of
 contact lenses.
     CIBA Vision is seeking to have the Court prohibit CooperVision from
 selling its infringing product.
     "This patent protects the innovative color technology of the FreshLook
 brand of contact lenses," said Scott Meece, vice president and general counsel
 for CIBA Vision.  "We are confident that we will prevail and we are eager to
 bring this case to trial.  We will take all steps necessary to prevent others
 from infringing on our intellectual property rights."
     CooperVision recently began selling its Frequency Colors in Florida and
 Puerto Rico.  CIBA Vision also has patent infringement litigation involving
 Frequency Colors pending in Germany, France and the U.K.
     CIBA Vision acquired Wesley Jessen on October 2, 2000, in an all cash
 transaction valued at $785 million.
     With worldwide headquarters in Atlanta, CIBA Vision is a global leader in
 research, development and manufacturing of optical and ophthalmic products and
 services, including contact lenses, lens care products and ophthalmic surgical
 products.  CIBA Vision products are available in more than 70 countries.  For
 more information, visit the CIBA Vision website at www.cibavision.com .
     CIBA Vision is the eye care unit of Novartis AG (NYSE:   NVS), a world
 leader in healthcare with core businesses in pharmaceuticals, consumer health,
 generics, eye care and animal health.  In 2000, the Group's ongoing businesses
 achieved sales of CHF 29.1 billion (USD 17.2 billion) and invested
 approximately CHF 4.0 billion (USD 2.4 billion) in R&D.  Headquartered in
 Basel, Switzerland, Novartis employs about 66,000 people and operates in more
 than 140 countries around the world.  For further information, please consult
 www.novartis.com .
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X18926423
 
 SOURCE  CIBA Vision Corporation